What amount sold does Transposagen Biopharmaceuticals, Inc. report in Form D filings?

The latest linked filings report $1.1M sold across 2 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Transposagen Biopharmaceuticals, Inc.'s most recent SEC filing?

Transposagen Biopharmaceuticals, Inc.'s most recent Form D filing was on 2012-07-18.

How many investors does Transposagen Biopharmaceuticals, Inc. have?

The most recent Form D filing lists 7 investor(s).

What type of securities does Transposagen Biopharmaceuticals, Inc. offer?

Transposagen Biopharmaceuticals, Inc.'s SEC Form D filings indicate equity offerings.

Transposagen Biopharmaceuticals, Inc.

CIK: 0001537601·Biotechnology·LEXINGTON, KY·Corporation·Founded 2011

Reported Sold

$1,080,000

Total Filings

Identified Offerings

Last Filed

Jul 18, 2012

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jul 18, 2012Form D — New notice

Reported sold: $355,000 · Target: $1,275,000

Rule 506·7 investors

Dec 20, 2011Form D — New notice

Reported sold: $725,000 · Target: $1,000,000

Rule 506·7 investors

Fundraising Profile

Exemptions

Rule 506

Investors in latest filing

Revenue Range

No Revenues

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 2 identified offerings

$1,080,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Eric M Ostertag

Related Person

Appears on 1 filing

Joseph Ruiz

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 18, 2012	New	$1,275,000	$355,000	7
Dec 20, 2011	New	$1,000,000	$725,000	7

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

511 Therapeutics, Inc.

Biotechnology

Offering target: $1,000,000

Filed Oct 30, 2026